Bosutinib is a dual inhibitor of Src and Abl kinases that is used as a treatment for patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML), who show resistance or intolerance to previous therapy, including imatinib. The gene discussed is SRC; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.